Copyright
©The Author(s) 2025.
World J Hepatol. Jun 27, 2025; 17(6): 104693
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.104693
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.104693
Figure 1 Diagnostic performance of glucagon0min in identifying metabolic dysfunction-associated steatotic liver disease in type 2 diabetes mellitus patients.
ROC: Receiver operating characteristic; AUC: Area under curve.
- Citation: Sun Y, Huang P, Zhao XQ, Tang ZQ, Xu TT, Wang XW, Qi ZX, Lin WR, Li MY, Gu YJ. Relationship between glucagon and metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus. World J Hepatol 2025; 17(6): 104693
- URL: https://www.wjgnet.com/1948-5182/full/v17/i6/104693.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i6.104693